Searle & CO. Acquires 75,250 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Searle & CO. increased its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 684.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 86,250 shares of the biotechnology company’s stock after purchasing an additional 75,250 shares during the period. Searle & CO. owned approximately 0.06% of Heron Therapeutics worth $172,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Congress Park Capital LLC boosted its position in Heron Therapeutics by 25.3% during the 3rd quarter. Congress Park Capital LLC now owns 1,978,078 shares of the biotechnology company’s stock worth $3,936,000 after acquiring an additional 399,577 shares during the last quarter. Squarepoint Ops LLC boosted its holdings in Heron Therapeutics by 369.0% during the second quarter. Squarepoint Ops LLC now owns 363,700 shares of the biotechnology company’s stock worth $1,273,000 after purchasing an additional 286,160 shares during the last quarter. BNP Paribas Financial Markets grew its position in Heron Therapeutics by 80.7% in the first quarter. BNP Paribas Financial Markets now owns 51,296 shares of the biotechnology company’s stock valued at $142,000 after purchasing an additional 22,904 shares in the last quarter. Marshall Wace LLP grew its position in Heron Therapeutics by 256.2% in the second quarter. Marshall Wace LLP now owns 1,761,051 shares of the biotechnology company’s stock valued at $6,164,000 after purchasing an additional 1,266,697 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in Heron Therapeutics by 16.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 45,771 shares of the biotechnology company’s stock valued at $160,000 after buying an additional 6,328 shares during the last quarter. 80.01% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC restated a “buy” rating and set a $5.00 price objective on shares of Heron Therapeutics in a research note on Wednesday, September 25th.

Heron Therapeutics Trading Up 1.4 %

Shares of Heron Therapeutics stock traded up $0.03 on Wednesday, reaching $1.81. 519,303 shares of the company were exchanged, compared to its average volume of 2,440,008. The company has a market capitalization of $271.93 million, a price-to-earnings ratio of -2.92 and a beta of 1.80. Heron Therapeutics, Inc. has a one year low of $0.50 and a one year high of $3.93. The company has a 50-day moving average of $1.90 and a 200 day moving average of $2.64.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The business had revenue of $36.02 million for the quarter, compared to analysts’ expectations of $35.35 million. During the same quarter in the prior year, the business earned ($0.35) earnings per share. Analysts predict that Heron Therapeutics, Inc. will post -0.1 earnings per share for the current year.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.